Argenx Shares Slip 0.81% Amid $250M in Volume Ranking 440th as Analysts Hike Price Targets on Rare Disease Growth Pipeline

On September 2, 2025, argenx (ARGX) closed with a 0.81% decline, trading at $704.00 per share. The stock recorded a volume of $250 million, ranking 440th in trading activity for the day. The move follows a series of analyst updates that highlighted evolving sentiment toward the biopharmaceutical firm. B of A Securities raised its price target to $887, maintaining a "Buy" rating, while other major firms including RBC Capital and JPMorgan also adjusted their positions to reflect optimism about argenx’s growth trajectory.

Analysts have consistently signaled confidence in argenx’s pipeline and market potential. Recent upgrades include Piper Sandler increasing its target to $820, RBC Capital initiating coverage with an $850 target, and JPMorgan raising its estimate to $830. These adjustments underscore a broader industry consensus that argenx’s therapeutic focus on rare autoimmune diseases positions it for long-term gains. The company’s lead product, Vyvgart, has expanded its indications to include Chronic Inflammatory Demyelinating Polyneuropathy, broadening its market reach and reinforcing its competitive edge.

With 23 analysts providing one-year price targets, the average estimate stands at $807.40, implying a 14.69% upside from the current price. The brokerage consensus score of 1.6 further supports a "Outperform" rating, reflecting strong institutional backing. Argenx’s strategic advancements in developing therapies for conditions such as primary immune thrombocytopenia and thyroid eye disease also contribute to its favorable outlook, despite short-term volatility in its stock price.

Based on historical data and analyst projections, the GF Value estimate suggests a potential 148.46% upside to $1,749.18 in one year. This projection, derived from past multiples and growth assumptions, aligns with the company’s ongoing efforts to expand its treatment portfolio and solidify its position in the biopharma sector.